3,5-dimethoxypicolinaldehyde | 1256790-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,5-dimethoxypicolinaldehyde
• 英文别名: 3,5-dimethoxypyridine-2-carbaldehyde
• CAS: 1256790-69-8
• 化学式: C₈H₉NO₃
• 分子量: 167.164
• InChiKey: ZTGUWYBOBMWZJX-UHFFFAOYSA-N

物化性质

• 沸点：
  306.1±37.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] AZACOUMARIN AND AZATHIOCOUMARIN DERIVATIVES FOR USE IN OPTICALLY ACTIVE DEVICES<br/>[FR] DÉRIVÉS D'AZACOUMARINES ET D'AZATHIOCOUMARINE DESTINÉS À ÊTRE UTILISÉS DANS DES DISPOSITIFS OPTIQUEMENT ACTIFS
  申请人：MERCK PATENT GMBH

  公开号：WO2021233800A1

  公开（公告）日：2021-11-25

  The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive chromophore, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices. The present invention is also directed to a process of changing the optical properties of said ophthalmic device or a precursor article for manufacturing said ophthalmic device.

  本发明涉及包括聚合物化合物的新型眼科器件，所述聚合物化合物包括光活性色素，以及特殊单体化合物，特别适用于眼科器件的组合物和眼科器件。本发明还涉及一种改变所述眼科器件的光学性能或用于制造所述眼科器件的前体物品的方法。
• [EN] CANCER THERAPEUTICS<br/>[FR] TRAITEMENTS ANTICANCÉREUX
  申请人：UNIV VIRGINIA PATENT FOUND

  公开号：WO2016025744A1

  公开（公告）日：2016-02-18

  This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and/or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and/or breast cancer.

  本发明涉及与野生型CBFβ结合并抑制CBFβ与RUNX蛋白结合的化合物。本发明的有效化合物以低微摩尔浓度抑制这种蛋白质-蛋白质相互作用，利用变构机制实现抑制，从细胞中置换野生型CBFβ从而改变RUNX1在靶基因上的占位率，改变RUNX1靶基因的基因表达。这些抑制剂表现出与靶向RUNX蛋白活性一致的明显生物学效应。含有本发明化合物和药学可接受载体的制药组合物代表该发明的另一实施形式。该发明的另一实施形式是通过向需要治疗的主体施用本发明化合物的治疗有效量来治疗表达野生型CBFβ的RUNX信号依赖性癌症。在一种实施形式中，该癌症被选自RUNX信号依赖性白血病，肺癌，膀胱癌，卵巢癌，子宫癌，子宫内膜癌，乳腺癌，肝癌，胰腺癌，胃癌，宫颈癌，淋巴瘤，白血病，急性髓性白血病，急性淋巴细胞白血病，涎腺癌，骨癌，脑癌，结肠癌，直肠癌，结直肠癌，肾癌，皮肤癌，黑色素瘤，舌鳞状细胞癌，多形性腺瘤，肝细胞癌，胰腺癌，鳞状细胞癌和/或腺癌。在另一实施形式中，本发明的化合物可用于治疗白血病，肺癌，卵巢癌和/或乳腺癌。
• Cancer therapeutics
  申请人：UNIVERSITY OF VIRGINIA PATENT FOUNDATION

  公开号：US10562890B2

  公开（公告）日：2020-02-18

  This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and/or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and/or breast cancer.

  本发明涉及与野生型 CBFβ 结合并抑制 CBFβ 与 RUNX 蛋白结合的化合物。本发明的强效化合物可在低微摩尔浓度下抑制这种蛋白-蛋白相互作用，利用异构机制实现抑制作用，将细胞中的野生型 CBFβ 从 RUNX1 中置换出来，改变 RUNX1 对靶基因的占有率，并改变 RUNX1 靶基因的基因表达。这些抑制剂显示出与靶上 RUNX 蛋白活性一致的明显生物效应。含有本发明化合物和药学上可接受的载体的药物组合物代表了本发明的另一个实施方案。本发明的另一个实施方案是通过向有需要的受试者施用治疗有效量的本发明化合物来治疗表达野生型 CBFβ 的 RUNX 信号依赖性癌症的方法。在一个实施方案中，所述癌症选自由表达野生型 CBFβ 的 RUNX 信号依赖性白血病、肺癌、膀胱癌、卵巢癌、子宫癌、子宫内膜癌、乳腺癌、肝癌、胰腺癌、胃癌、宫颈癌、淋巴瘤、白血病、急性髓性白血病、急性淋巴细胞白血病、急性淋巴细胞白血病、急性髓细胞白血病、急性淋巴细胞白血病、唾液腺癌、骨癌、脑癌、结肠癌、直肠癌、结直肠癌、肾癌、皮肤癌、黑色素瘤、舌鳞癌、多形性腺瘤、肝细胞癌、胰腺癌、鳞状细胞癌和/或腺癌。在另一个实施方案中，本发明的化合物可用于治疗白血病、肺癌、卵巢癌和/或乳腺癌。
• CANCER THERAPEUTICS
  申请人：University Of Virginia Patent Foundation

  公开号：EP3180004A1

  公开（公告）日：2017-06-21